Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

56 results about "Targeted immunotherapy" patented technology

Broadly speaking, immunotherapy is the use of immune cells from the patients or a donor to elicit an anti-cancer effect. Targeted therapy, is a therapy that aims to specifically target cancer cells, while sparing healthy cells.

Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs

The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and / or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.
Owner:DRUG INNOVATION & DESIGN

Human Anti-Tau Antibodies

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:UNIV ZURICH +1

Compounds for targeted immunotherapy

Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Owner:BIRDIE BIOPHARM INC

Method for enhancing specific immunotherapies in cancer treatment

Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
Owner:PROVIDENCE HEALTH & SERVICES OREGON D B A EARLE A CHILES RES INST OF THE ROBERT W FRANZ CANCER RES CENT AT PROVIDENCE PORTLAND MEDICAL CENT +1

Human Anti-tau antibodies

Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1

Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation

InactiveUS20050137384A1Extended half-lifeAltering pharmacology and biodistributionPeptide/protein ingredientsAntibody mimetics/scaffoldsWhite blood cellStepwise approach
Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.
Owner:MERCK PATENT GMBH

Human anti-tau antibodies

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:UNIV ZURICH +1

Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation

InactiveUS7226998B2Altering pharmacology and biodistributionIncreasing its circulating half-life and its affinityPeptide/protein ingredientsAntibody mimetics/scaffoldsStepwise approachImmune therapy
Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.
Owner:MERCK PATENT GMBH

Compounds and Compositions for Treating EGFR Expressing Tumors

Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors / cancers. Also provided are compositions comprising the compounds.
Owner:BIRDIE BIOPHARM INC

Compounds for targeted immunotherapy

Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Owner:BIRDIE BIOPHARM INC

Compounds for targeted immunotherapy

Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.
Owner:BIRDIE BIOPHARM INC

Human anti-alpha-synuclein antibodies

Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1

Methods and compositions for pharmacologially controlled targeted immunotherapy

InactiveUS20070134259A1Promotes complement-mediated cytotoxicityOrganic active ingredientsBiocideMolecular Targeted TherapiesTargeted immunotherapy
The present invention relates generally to methods and compositions for targeted immunotherapy. More specifically, the present invention relates to immuno-targeted therapies, using heteromultivalent compounds to mediate the binding of an endogenous effector molecule such as an antibody to target molecules including malignant cells and tissues, bacteria and viruses as well as their toxic agents.
Owner:THE GOVERNORS OF THE UNIV OF ALBERTA

Human Anti-Alpha-Synuclein Antibodies

Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for α-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1

Novel Anti-fibroblast activation protein (FAP) binding agents and uses thereof

InactiveUS20180022822A1Enhance tumor targeting tumorEnhance tumor tumor selectivityAntibody mimetics/scaffoldsAntipyreticAntigenAntigen receptors
Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
Owner:MABIMMUNE DIAGNOSTICS AG

Human Anti-tau antibodies

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN MA INC +1

Human anti-tau antibodies

Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN MA INC +1

Anti-α synuclein binding molecules

ActiveUS9580493B2Reduce riskPreventing a clinically manifest synucleinopathic diseaseNervous disorderImmunoglobulins against animals/humansEpitopeAntigen Binding Fragment
Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1

Compound for immunotherapy, and composition

The present invention relates to a compound for targeting immunotherapy, and a composition containing the compound. The present invention further relates to applications of the compound in treatment of diseases such as cancers.
Owner:BIRDIE BIOPHARM INC

Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor

Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and / or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and / or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.
Owner:NEURIMMUNE HLDG

Human anti-SOD1 antibodies

ActiveCN103380145AMonitor disease progressionMonitor therapeuticMuscular disorderVertebrate antigen ingredientsDismutaseSuperoxide dismutases
Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
Owner:NEURIMMUNE HLDG +1

Method for enhancing specific immunotherapies in cancer treatment

Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.
Owner:PROVIDENCE HEALTH & SERVICES OREGON D B A EARLE A CHILES RES INST OF THE ROBERT W FRANZ CANCER RES CENT AT PROVIDENCE PORTLAND MEDICAL CENT +1

Tdp-43 specific binding molecules

Provided are novel TDP-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.
Owner:UNIV ZURICH +1

Anti-Alpha Synuclein Binding Molecules

Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human α-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for α-synuclein targeted immunotherapy and diagnosis, respectively.
Owner:BIOGEN INT NEUROSCI +1

Anti PD-L1 conjugates for treating tumors

The present invention discloses anti-PD-L / PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor / cancer.
Owner:BIRDIE BIOPHARM INC

HER2 positive tumor targeting compound and composition thereof

The present invention provides a HER2 positive tumor targeting compound and a composition thereof, and relates to a compound used for the targeting immunotherapy method, and a composition containing the compound. The present invention further relates to applications of the compound in treatment of HER2-positive tumors / cancers.
Owner:BIRDIE BIOPHARM INC

Human-derived Anti-dipeptide repeats (DPRS) antibody

Provided are novel human-derived dipeptide repeat (DPR) specific antibodies as well as synthetic variants and biotechnological derivatives thereof, preferably capable of binding C9ORF72 DPRs, as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for DPRs and DPR proteins such C9ORF72 DPRs are also disclosed. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.
Owner:NEURIMMUNE HLDG

Autoimmune encephalitis antibody transient transfection and stable transfection detection method and application thereof

The invention provides an autoimmune encephalitis antibody transient transfection and stable transfection detection method and application thereof. Specifically, the invention provides a recombinant cell for expressing mutant NMDAR, the recombinant cell expresses fusion protein of exogenous mutant NMDAR and fluorescent protein, and the transfection survival rate is high. The recombinant cell provided by the invention can be used for detecting antibodies related to autoimmune encephalitis, including NMDAR, AMPAR1, AMPAR2, LGI1, Caspr2 and GABABR. The invention also provides a method for detecting anti-autoimmune encephalitis by using the transfected cell line through an indirect immunofluorescence method based on the recombinant transfected cell line provided by the invention. The method disclosed by the invention has high sensitivity and specificity, and can be used for accurately detecting the types of pathogenic antibodies so as to help a patient to carry out targeted immunotherapy and recover health.
Owner:陈向军

Conjugate of influenza A virus conservative peptides M2e and virus-like particles, and application thereof

The invention relates to a conjugate of virus-like particles (VLP) of oligopeptide vector Q[beta] bacteriophage with target immunotherapy and conservative peptides M2e of human influenza virus M2 protein. The conjugate is mainly used for preventing human influenza A. The conjugate is coupled by a Sulfo-SMCC method which comprises a first step of preparing the virus-like particles (VLP) of the Q[beta] bacteriophage; a second step of preparing the virus-like particles (VLP) activated by Sulfo-SMCC; and a third step of preparing the conjugate of M2e-VLP. The conjugate can produce high titer protective antibody in mice and cross-protect the attack of various subtypes of the influenza A viruses.
Owner:苏州科贝生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products